Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1985 Jul;28(1):146–148. doi: 10.1128/aac.28.1.146

Comparison of ceftazidime with cefamandole for therapy of community-acquired pneumonia.

J C Engle, P W Lifland, C J Schleupner
PMCID: PMC176328  PMID: 3899002

Abstract

Ceftazidime and cefamandole were compared in the treatment of pneumonia. The median MIC of ceftazidime for all Streptococcus pneumoniae (n = 17) and Haemophilus influenzae (n = 10) isolates was 0.125 microgram/ml. All other isolates were inhibited by less than 0.5 microgram of ceftazidime per ml, with the exception of a group B streptococcus (MIC = 4 micrograms/ml). Satisfactory clinical responses were observed in 91% (20 of 22) of cefamandole-treated patients and 85% (17 of 20) of ceftazidime-treated patients.

Full text

PDF
146

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bauer A. W., Kirby W. M., Sherris J. C., Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 1966 Apr;45(4):493–496. [PubMed] [Google Scholar]
  2. Clumeck N., Van Laethem Y., Gordts B., Jaspar N., Butzler J. P. Use of ceftazidime in the therapy of serious infections, including those due to multiresistant organisms. Antimicrob Agents Chemother. 1983 Aug;24(2):176–180. doi: 10.1128/aac.24.2.176. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Custer G. M., Briggs B. R., Smith R. E. Effect of cefamandole nafate on blood coagulation and platelet function. Antimicrob Agents Chemother. 1979 Dec;16(6):869–872. doi: 10.1128/aac.16.6.869. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Ericsson H. M., Sherris J. C. Antibiotic sensitivity testing. Report of an international collaborative study. Acta Pathol Microbiol Scand B Microbiol Immunol. 1971;217(Suppl):1+–1+. [PubMed] [Google Scholar]
  5. Eron L. J., Goldenberg R. I., Park C. H., Poretz D. M. Ceftazidime therapy of serious bacterial infections. Antimicrob Agents Chemother. 1983 Feb;23(2):236–241. doi: 10.1128/aac.23.2.236. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fainstein V., Bodey G. P., McCredie K. B., Keating M. J., Estey E. H., Bolivar R., Elting L. Coagulation abnormalities induced by beta-lactam antibiotics in cancer patients. J Infect Dis. 1983 Oct;148(4):745–750. doi: 10.1093/infdis/148.4.745. [DOI] [PubMed] [Google Scholar]
  7. Fu K. P., Aswapokee P., Ho I., Matthijssen C., Neu H. C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother. 1979 Nov;16(5):592–597. doi: 10.1128/aac.16.5.592. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gozzard D. I., Geddes A. M., Farrell I. D., Eykyn S. J., Phillips I., Wise R., Brown R. M. Ceftazidime--a new extended-spectrum cephalosporin. Lancet. 1982 May 22;1(8282):1152–1156. doi: 10.1016/s0140-6736(82)92228-0. [DOI] [PubMed] [Google Scholar]
  9. Greenwood D., Eley A. Comparative antipseudomonal activity of some newer beta-lactam agents. Antimicrob Agents Chemother. 1982 Feb;21(2):204–209. doi: 10.1128/aac.21.2.204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Jones R. N., Barry A. L., Thornsberry C. Disk agar diffusion susceptibility testing with 30-micrograms ceftazidime disks: confirmation of interpretive breakpoints and quality control guidelines. J Clin Microbiol. 1983 Jul;18(1):211–214. doi: 10.1128/jcm.18.1.211-214.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kemmerich B., Warns H., Lode H., Borner K., Koeppe P., Knothe H. Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora. Antimicrob Agents Chemother. 1983 Sep;24(3):333–338. doi: 10.1128/aac.24.3.333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Lüthy R., Blaser J., Bonetti A., Simmen H., Wise R., Siegenthaler W. Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime. Antimicrob Agents Chemother. 1981 Nov;20(5):567–575. doi: 10.1128/aac.20.5.567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Murray P. R., Washington J. A. Microscopic and baceriologic analysis of expectorated sputum. Mayo Clin Proc. 1975 Jun;50(6):339–344. [PubMed] [Google Scholar]
  14. Muytjens H. L., van der Ros-van de Repe J. Comparative activities of 13 beta-lactam antibiotics. Antimicrob Agents Chemother. 1982 Jun;21(6):925–934. doi: 10.1128/aac.21.6.925. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Nelson J. D., Kusmiesz H., Shelton S. Oral or intravenous trimethoprim-sulfamethoxazole therapy for shigellosis. Rev Infect Dis. 1982 Mar-Apr;4(2):546–550. doi: 10.1093/clinids/4.2.546. [DOI] [PubMed] [Google Scholar]
  16. Neu H. C. Cefamandole, a cephalosporin antibiotic with an unusually wide spectrum of activity. Antimicrob Agents Chemother. 1974 Aug;6(2):177–182. doi: 10.1128/aac.6.2.177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Neu H. C. Cefoxitin, a semisynthetic cephamycin antibiotic: antibacterial spectrum and resistance to hydrolysis by gram-negative beta-lactamases. Antimicrob Agents Chemother. 1974 Aug;6(2):170–176. doi: 10.1128/aac.6.2.170. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Neu H. C., Labthavikul P. Antibacterial activity and beta-lactamase stability of ceftazidime, an aminothiazolyl cephalosporin potentially active against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1982 Jan;21(1):11–18. doi: 10.1128/aac.21.1.11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Neu H. C. The new beta-lactamase-stable cephalosporins. Ann Intern Med. 1982 Sep;97(3):408–419. doi: 10.7326/0003-4819-97-3-408. [DOI] [PubMed] [Google Scholar]
  20. O'Callaghan C. H., Acred P., Harper P. B., Ryan D. M., Kirby S. M., Harding S. M. GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity. Antimicrob Agents Chemother. 1980 May;17(5):876–883. doi: 10.1128/aac.17.5.876. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Reed M. D., O'Brien C. A., Aronoff S. C., Klinger J. D., Blumer J. L. Ceftazidime as initial therapy for suspected bacterial infections in hospitalized pediatric patients. Antimicrob Agents Chemother. 1984 Sep;26(3):318–321. doi: 10.1128/aac.26.3.318. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Rusconi F., Assael B. M., Florioli A., Zaffaroni G. Ceftazidime in the treatment of pediatric patients with severe urinary tract infections due to Pseudomonas spp. Antimicrob Agents Chemother. 1984 Mar;25(3):395–397. doi: 10.1128/aac.25.3.395. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Sanders C. C., Moellering R. C., Jr, Martin R. R., Perkins R. L., Strike D. G., Gootz T. D., Sanders W. E., Jr Resistance to cefamandole: a collaborative study of emerging clinical problems. J Infect Dis. 1982 Jan;145(1):118–125. doi: 10.1093/infdis/145.1.118. [DOI] [PubMed] [Google Scholar]
  24. Sanders C. C., Sanders W. E., Jr Emergence of resistance during therapy with the newer beta-lactam antibiotics: role of inducible beta-lactamases and implications for the future. Rev Infect Dis. 1983 Jul-Aug;5(4):639–648. doi: 10.1093/clinids/5.4.639. [DOI] [PubMed] [Google Scholar]
  25. Sanders C. C., Sanders W. E., Jr Emergence of resistance to cefamandole: possible role of cefoxitin-inducible beta-lactamases. Antimicrob Agents Chemother. 1979 Jun;15(6):792–797. doi: 10.1128/aac.15.6.792. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Schleupner C. J., Engle J. C. Clinical evaluation of cefotaxime for therapy of lower respiratory tract infections. Antimicrob Agents Chemother. 1982 Feb;21(2):327–333. doi: 10.1128/aac.21.2.327. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Tillotson J. R., Finland M. Bacterial colonization and clinical superinfection of the respiratory tract complicating antibiotic treatment of pneumonia. J Infect Dis. 1969 Jun;119(6):597–624. doi: 10.1093/infdis/119.6.597. [DOI] [PubMed] [Google Scholar]
  28. Tjandramaga T. B., Van Hecken A., Mullie A., Verbesselt R., De Schepper P. J., Verbist L. Comparative pharmacokinetics of ceftazidime and moxalactam. Antimicrob Agents Chemother. 1982 Aug;22(2):237–241. doi: 10.1128/aac.22.2.237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Verbist L. Comparison of in vitro activities of eight beta-lactamase-stable cephalosporins against beta-lactamase-producing gram-negative bacilli. Antimicrob Agents Chemother. 1981 Mar;19(3):407–413. doi: 10.1128/aac.19.3.407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Verbist L., Verhaegen J. GR-20263: a new aminothiazolyl cephalosporin with high activity against Pseudomonas and Enterobacteriaceae. Antimicrob Agents Chemother. 1980 May;17(5):807–812. doi: 10.1128/aac.17.5.807. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Weitekamp M. R., Aber R. C. Prolonged bleeding times and bleeding diathesis associated with moxalactam administration. JAMA. 1983 Jan 7;249(1):69–71. [PubMed] [Google Scholar]
  32. Wise R., Rollason T., Logan M., Andrews J. M., Bedford K. A. HR 756, a highly active cephalosporin: comparison with cefazolin and carbenicillin. Antimicrob Agents Chemother. 1978 Dec;14(6):807–811. doi: 10.1128/aac.14.6.807. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES